Ticker >

Kwality Pharma share price

Kwality Pharmaceuticals Ltd.

BSE: 539997 SECTOR: Pharmaceuticals & Drugs  39k   346   13

506.00
+11.55 (2.34%)
BSE: Today, 12:13 PM

Price Summary

Today's High

₹ 519.15

Today's Low

₹ 501

52 Week High

₹ 545

52 Week Low

₹ 248

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

525.04 Cr.

Enterprise Value

609.21 Cr.

No. of Shares

1.04 Cr.

P/E

43.56

P/B

2.38

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  212.55

CASH

6.09 Cr.

DEBT

90.26 Cr.

Promoter Holding

54.83 %

EPS (TTM)

₹  11.62

Sales Growth

-44.97%

ROE

10.17 %

ROCE

12.28%

Profit Growth

-83.78 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-44.97%
3 Year21.86%
5 Year12.9%

Profit Growth

1 Year-83.78%
3 Year32.17%
5 Year33.01%

ROE%

1 Year10.17%
3 Year45.78%
5 Year35.91%

ROCE %

1 Year12.28%
3 Year45.33%
5 Year35.2%

Debt/Equity

0.4486

Price to Cash Flow

12.45

Interest Cover Ratio

4.89873781705914

CFO/PAT (5 Yr. Avg.)

0.856509688483527

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 54.83 0
Dec 2023 54.77 0
Sep 2023 54.77 0
Jun 2023 54.74 0
Mar 2023 54.74 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 32.1736184997725% for the Past 3 years.
  • The company has shown a good revenue growth of 21.8649310780789% for the Past 3 years.
  • Company has been maintaining healthy ROE of 45.7754998956157% over the past 3 years.
  • Company has been maintaining healthy ROCE of 45.3254195019957% over the past 3 years.
  • The company has an efficient Cash Conversion Cycle of 23.05923150236 days.
  • The company has a high promoter holding of 54.83%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.46401440014116.

 Limitations

 Looks like the company does not have any serious limitations.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 56.01 68.8 67.45 69.65 78.1
Total Expenditure 40.84 57.29 53.64 54.38 61.39
Operating Profit 15.17 11.52 13.81 15.27 16.7
Other Income 0.35 1.46 0.4 0.23 0.62
Interest 1.95 1.67 2.19 2.41 2.73
Depreciation 3.54 4.42 4.78 4.88 4.81
Exceptional Items 0 -16.53 0 0 0
Profit Before Tax 10.03 -9.63 7.24 8.21 9.78
Tax 2.8 -2.28 1.79 1.95 2.07
Profit After Tax 7.23 -7.36 5.45 6.26 7.7
Adjusted EPS (Rs) 6.96 -7.09 5.25 6.03 7.42

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 165.15 138.68 261.5 456.13 250.99
Total Expenditure 149.91 124.57 232.24 284.41 190.12
Operating Profit 15.24 14.12 29.26 171.72 60.88
Other Income 0.93 3.92 1.59 3.51 2.94
Interest 2.21 2.5 2.62 2.92 6.61
Depreciation 3.06 4.39 6.44 10.64 14.92
Exceptional Items 0 0 0 0 -16.53
Profit Before Tax 10.9 11.14 21.8 161.67 25.76
Tax 3.35 2.71 6.38 41.63 6.29
Net Profit 7.55 8.43 15.42 120.05 19.47
Adjusted EPS (Rs.) 7.27 8.13 14.86 115.69 18.76

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 10.38 10.38 10.38 10.38 10.38
Total Reserves 28.29 36.72 52.13 172.18 191.65
Borrowings 7.01 10.18 18.26 20.29 27.3
Other N/C liabilities 0.64 9.6 9.82 1.03 1.31
Current liabilities 60.67 67.61 78.15 138.8 125.94
Total Liabilities 106.99 134.48 168.75 342.68 356.58
Assets
Net Block 21.54 41.63 55.52 90.77 119.57
Capital WIP 6.48 0 2.89 12.15 14.29
Intangible WIP 0 0 0 0 0
Investments 4.64 4.2 4.28 3.55 3.55
Loans & Advances 0.12 0.12 0.17 8.11 10.71
Other N/C Assets 0.03 0 0 0.78 0.93
Current Assets 74.17 88.53 105.88 227.32 207.52
Total Assets 106.99 134.48 168.75 342.68 356.58
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 10.9 11.14 21.8 161.67 25.76
Adjustment 4.74 6.27 8.98 13.51 20.91
Changes in Assets & Liabilities 0.76 -9.06 1.96 -74.59 1.67
Tax Paid -3.44 -2.71 -6.38 -41.35 -6.16
Operating Cash Flow 12.96 5.63 26.36 59.24 42.19
Investing Cash Flow -11.8 -17.13 -23.2 -62.98 -48.44
Financing Cash Flow -1.91 12.36 0.83 5.66 0.99
Net Cash Flow -0.75 0.87 3.99 1.93 -5.26

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 54.74 54.74 54.77 54.77 54.83
aditya arora 6.86 11.86 11.89 11.89 11.95
ajay arora - 13.59 13.59 13.59 13.59
anju arora 1.31 1.31 1.31 1.31 1.31
geeta arora 1.07 1.07 1.07 1.07 1.07
jugal kishore huf 0.89 0.89 0.89 0.89 0.89
ramesh arora 31.01 26.01 26.01 26.01 26.01
ajay kumar arora 13.59 - - - -
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 45.26 45.26 45.23 45.23 45.17
deepak bansal 10.54 10.60 10.63 10.63 10.63
dheeraj kumar lohia - - - 1.92 1.92
investor education and pr... - - - - 0.97
jani bhasha shaik 1.45 1.45 1.45 1.45 1.45
kadayam ramnathan bharat - - - 1.16 1.66
manohar devabhaktuni 4.83 4.98 4.98 4.98 4.98
onkar singh - 1.02 1.02 1.02 1.02
aknm suppliers private li... 8.21 3.77 - - -
sunidhi securities & fina... 1.12 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

  • PresentationQ4FY22 21 Jun 2022

Company News

Kwality Pharma - Quaterly Results6 Feb 2024, 7:40PM Kwality Pharma - Quaterly Results6 Feb 2024, 7:40PM Kwality Pharmaceuticals informs about confirmation certificate15 Jan 2024, 12:19PM Kwality Pharma - Quaterly Results4 Nov 2023, 8:48PM Kwality Pharma - Quaterly Results10 Aug 2023, 7:21PM Kwality Pharma - Quaterly Results10 Aug 2023, 7:21PM Kwality Pharmaceuticals informs about disclosure 1 Jul 2023, 2:20PM Kwality Pharmaceuticals informs about disclosure9 Jun 2023, 12:15PM Kwality Pharma - Quaterly Results27 May 2023, 8:12PM Kwality Pharmaceuticals gets EU GMP approval for Himachal Pradesh facility24 Apr 2023, 5:58PM Kwality Pharmaceuticals informs about change in directorate17 Mar 2023, 2:38PM Kwality Pharma - Quaterly Results14 Feb 2023, 8:30PM Kwality Pharmaceuticals informs about disclosure21 Jan 2023, 3:45PM Kwality Pharmaceuticals informs about disclosure21 Jan 2023, 2:56PM Kwality Pharmaceuticals informs about confirmation certificate10 Jan 2023, 11:51AM Bulgarian Drug Agency accepts Kwality Pharmaceuticals’ application for EU Audit visit of HP plant28 Dec 2022, 9:57AM Kwality Pharmaceuticals gets approval from Brazil's ANVISA 21 Dec 2022, 4:00PM Kwality Pharmaceuticals informs about disclosure of related party transactions29 Nov 2022, 9:42AM Kwality Pharma - Quaterly Results14 Nov 2022, 12:00PM Kwality Pharmaceuticals informs about press release17 Aug 2022, 12:31PM Kwality Pharmaceuticals informs about disclosure27 Jun 2022, 11:16AM Kwality Pharmaceuticals informs about closure of trading window1 Apr 2022, 9:49AM Kwality Pharmaceuticals informs about disclosure28 Feb 2022, 9:29AM Kwality Pharmaceuticals informs about disclosure5 Feb 2022, 2:48PM Kwality Pharmaceuticals informs about confirmation certificate18 Jan 2022, 10:11AM Kwality Pharmaceuticals informs about annual report8 Sep 2021, 9:54AM Kwality Pharmaceuticals informs about disclosure26 Jun 2021, 11:13AM

Kwality Pharma Stock Price Analysis and Quick Research Report. Is Kwality Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Kwality Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Kwality Pharma cash from the operating activity was Rs 42.1876 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Kwality Pharma has a Debt to Equity ratio of 0.4486 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Kwality Pharma , the EPS growth was -83.7823330815201 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Kwality Pharma has OPM of 24.2538587468182 % which is a good sign for profitability.
     
  • ROE: Kwality Pharma have a average ROE of 10.1669609801199 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Kwality Pharma is Rs 494.45. One can use valuation calculators of ticker to know if Kwality Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Kwality Pharma
X